There are new allegations against a metro doctor who ran a weight loss surgery clinic that shut down this summer. Court documents show that Dr. Stephen Malley failed a drug test. “He was supposed to make life better, but instead he’s made life a lot more The FDA’s recent approval of a new prescription weight loss pill offers yet another option for the more than one-third of American adults who affected by obesity. Called Contrave, the new drug is the third prescription weight loss drug to be approved by NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule. Orexigen said it still having Results of a phase 2 clinical study suggest that the weight-loss drug, lorcaserin hydrochloride (Belviq), is also an effective smoking cessation aid. In the randomized 12-week trial, 603 active smokers participated in tobacco cessation counseling in American obesity rates are skyrocketing and consumers place great faith in weight loss pills and remedies to look beyond the marketing and find real information about a drug was very effective in reducing their false expectations and unhealthy behavior. In supplements bought online, researchers detected hidden steroids, similar ingredients to Viagra and Prozac and a weight loss drug linked with heart attacks. They tested 27 products promising big muscles, sexual prowess, weight loss and more. Of those .
Americans spend about $4 billion a year on weight-loss supplements. And the Food and Drug Administration spends a lot of effort policing distributors who market fraudulent products that are tainted with unsafe, banned drugs. But a study published Tuesday With Orexigen and Takeda’s weight-loss drug Contrave (naltrexone and bupropion) on the market as of last month, the triumvirate of new prescription obesity medications, which includes Vivus’s Qsymia (phentermine and topiramate) and the Arena/Eisai drug In this case, it is about exploring the use of its weight-loss drug Belviq (lorcaserin) as a smoking-cessation aid. Phase-II results published November 3 showed “statistically significant improvement over placebo in reducing the number of patients who The U.S. Food and Drug Administration is likely to approve Novo Nordisk’s new drug to treat obesity this year, analysts said after wide expectations of an FDA decision late on Monday were not met. Danish drugmaker Novo Nordisk applied for approval for .